Upsher-Smith warning letter
This article was originally published in The Tan Sheet
Executive Summary
Originally posted on FDA's Web site, warning letter for firm's Slo-Niacin supplement was rescinded and eventually removed from site because it had not been approved through appropriate FDA channels, according to counsel for Upsher-Smith. All warning letters are now being reviewed by the agency's Office of Chief Counsel before they are released. 1"The Tan Sheet" Oct. 7, 2002, p. 16 cited a warning letter deeming Slo-Niacin a misbranded new drug...
You may also be interested in...
Niacin Supplement For High Cholesterol Targeted In Warning Letter
Upsher-Smith Labs' Slo-Niacin was cited by FDA in a recent warning letter for claims it has made to treat hypercholesterolemia
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.